By Market & Region

SHERIDAN, WYOMING – August 27, 2025 – The 39th International Trade Fair for Retail Promotions and Imports (IAW) is set to return to Cologne from September 2–4, 2025, bringing together 280 exhibitors from over 30 countries and thousands of professional buyers. Positioned as Europe’s leading ordering platform for retail promotions, the event continues to blend product diversity, competitive sourcing, and forward-looking e-commerce strategies under one roof.

A Marketplace for Retail Innovation

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona has announced a landmark donation to Atlanta’s Ben Massell Dental Clinic, equipping the historic nonprofit with state-of-the-art digital dentistry technologies. The initiative marks one of the most significant technology upgrades in the clinic’s century-long history, designed to expand access to care for underserved patients while streamlining clinical workflows.

Transforming Care with Digital Dentistry

The donation includes an integrated digital suite featuring two Primescan AC intraoral scanners, a CEREC Primemill milling machine, a CEREC SpeedFire sintering furnace, and a Primeprint 3D printer. Together, these tools will enable the clinic to offer same-day crowns, bridges, and faster denture turnaround times—reducing processes that once took months to a matter of days.

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona has broadened its chairside implant portfolio with the launch of the CEREC Tessera® Abutment Block and complementary Calibra® Abutment Resin Cement. The new solution enables clinicians to fabricate hybrid abutments and fully contoured abutment crowns directly in-office, accelerating implant workflows while maintaining high esthetic and mechanical performance.

Advancing Chairside CAD/CAM Implantology

The CEREC Tessera® Abutment Block extends the company’s Advanced Lithium Disilicate (ALD) platform, already known for its strength and esthetics in CAD/CAM restorations. Designed with a pre-drilled screw access channel and anti-rotation feature, the new block supports both hybrid abutments bonded to TiBases and screw-retained hybrid abutment crowns.

Key benefits include:

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, has released its 2024 Sustainability Report, highlighting significant achievements across environmental, social, and governance pillars. The company surpassed several of its 2025 targets ahead of schedule and introduced a new long-term commitment: achieving 100% recyclable packaging by 2030.

Advancing Sustainability Through the BEYOND Strategy

Since 2021, Dentsply Sirona has driven its ESG roadmap under the strategy “BEYOND: Taking Action for a Brighter World.” The 2024 report shows meaningful gains across its three pillars — Healthy Planet, Healthy Smiles, and Healthy Business — with tangible results for the dental industry and global stakeholders.

Key highlights include:

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona has reinforced its commitment to widening access to oral healthcare through its fourth annual Miles for Smiles charity walk, raising £18,000 to support underserved communities across the UK and Ireland. The initiative, part of the company’s broader BEYOND: Taking Action for a Brighter World sustainability program, reflects the dental technology leader’s continued alignment of corporate responsibility with community health needs.

Walking for Change in Oral Health

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona is intensifying its commitment to digital orthodontics with the launch of a global educational webinar series built around its SureSmile platform. The initiative aims to help orthodontists and dental teams integrate advanced digital workflows into everyday practice, driving improvements in treatment planning, patient outcomes, and practice efficiency.

Advancing Clinical Education in Digital Orthodontics

The SureSmile Global Specialist Educational Webinars are structured to address the rapid adoption of digital technologies across orthodontics. Each session focuses on a core element of digital treatment planning, offering step-by-step insights from leading practitioners.

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona, the FDI World Dental Federation (FDI), and Smile Train have expanded their joint cleft care education program, introducing multilingual access to their digital training platform and new workflow videos aimed at improving cleft treatment globally. The initiative, timed with Cleft Awareness Month, underscores a strategic push to equip dental professionals with advanced tools, protocols, and training to address one of the most common congenital conditions affecting children worldwide.

Expanding Global Reach Through Multilingual Training

SHERIDAN, WYOMING – August 26, 2025 – The ECR Tag 2025 in Cologne is set to bring together leaders from retail, consumer goods, and technology for two days of strategy-focused exchange, highlighting how AI, collaboration, and consumer-centric innovation are redefining competitive growth models in the sector.

AI-Driven Retail Transformation on the Agenda
Artificial intelligence will be a central theme at this year’s event, with executives from Amazon Web Services outlining how AI agents are reshaping category management and retail operations. The focus extends beyond automation, emphasizing decision intelligence, real-time personalization, and supply chain optimization as key levers for retailers adapting to shifting consumer expectations.

SHERIDAN, WYOMING – August 26, 2025 – GS1 Germany and Meta are set to co-host the Retail Summit 2025 on November 5 in Cologne, bringing together leading retailers, technology providers, and brand executives to explore how artificial intelligence, retail media, and immersive experiences are reshaping commerce across Europe. Under the theme “Where Technology Meets Experience,” the event aims to highlight best practices from both established brands and Silicon Valley innovators.

A Platform for Retail AI and Emerging Technologies

SHERIDAN, WYOMING – August 26, 2025 – Zukunft Personal Europe (ZP Europe) is set to mark its 25th anniversary with a forward-looking edition in Cologne from September 9–11, 2025. Positioned under the theme “Time for New Beginnings”, the event will move beyond retrospectives to highlight transformation strategies, cutting-edge HR technology, and organizational models for a rapidly evolving workplace.

From HR Fair to European Transformation Hub

Once launched as a specialized HR trade fair, Zukunft Personal has evolved into Europe’s leading platform for people and organizational performance. In 2025, the anniversary event aims to showcase how businesses can address interconnected challenges in leadership, digitalization, workplace culture, and resilience. Organizers emphasize that the focus is no longer just human resources, but broader structural change shaping enterprises across industries.

SHERIDAN, WYOMING – August 12, 2025 – Eli Lilly’s Phase III results for its next-generation oral GLP-1 therapy, orforglipron, have energized the already competitive obesity drug market, sparking renewed focus on oral weight-loss candidates poised to challenge the injectable-dominated landscape. While Lilly’s data confirmed significant efficacy, industry analysts see room for competitors to gain ground with differentiated mechanisms, dosing advantages, and manufacturing scalability.

The ATTAIN-1 study showed orforglipron achieved an average 12.4% weight reduction over 72 weeks, compared with 0.9% for placebo, with nearly 60% of high-dose patients losing at least 10% of body weight. However, analysts at Truist Securities and William Blair noted the therapy’s performance fell short of expectations set by leading injectable GLP-1 agonists—creating an opening for rivals.

Market Shift Toward Oral Obesity Therapies

SHERIDAN, WYOMING – August 12, 2025 – A wave of safety concerns surrounding adeno-associated virus (AAV) gene therapy has hit the biotechnology sector following multiple patient deaths linked to Sarepta Therapeutics’ platform. While some stakeholders push for urgent refinements to the decades-old technology, others are accelerating work on alternative delivery systems that could reshape the future of genetic medicine.

SHERIDAN, WYOMING – August 12, 2025 – The Department of Health and Human Services (HHS) is facing fresh turbulence after the abrupt dismissal of Gray Delany, the lead implementor of the Make America Healthy Again (MAHA) initiative. The move comes just days after Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine contracts worth a combined $500 million, triggering intense debate across the biomedical and public health sectors.

SHERIDAN, WYOMING – August 12, 2025 – The U.S. Food and Drug Administration (FDA) has significantly tightened prescribing criteria for bluebird bio’s Skysona, an autologous hematopoietic stem cell-based gene therapy for cerebral adrenoleukodystrophy (CALD). The treatment is now limited to patients with no other therapeutic options or available stem cell donors, following post-marketing findings of a substantially higher incidence of hematologic malignancies than previously reported.

SHERIDAN, WYOMING – August 11, 2025 – The U.S. pharmaceutical sector faces a pivotal moment as recent federal funding cuts to mRNA vaccine programs threaten to slow one of oncology’s most promising frontiers: dendritic cell–based mRNA cancer immunotherapies. With the Department of Health and Human Services ending approximately $500 million in BARDA contracts, industry stakeholders are being called upon to bridge the gap and accelerate clinical translation.

Why mRNA Technology Is Critical for Cancer Immunotherapy

SHERIDAN, WYOMING – August 11, 2025 – Boehringer Ingelheim has secured FDA accelerated approval for its kinase inhibitor Hernexeos (zongertinib), marking the German pharmaceutical company’s first entry into the oncology market in its 140-year history. The approval positions Hernexeos as a new targeted therapy for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)–activating mutations.

Targeted Innovation in HER2-Mutant NSCLC
Hernexeos is designed as an oral, selective, and irreversible HER2 inhibitor that disrupts cell growth and division driven by HER2 signaling. By directly addressing this oncogenic pathway, the drug aims to provide a new treatment option for a patient subset that historically faces poor prognoses and limited targeted therapy choices.

SHERIDAN, WYOMING – August 10, 2025 – Midea Group will make a significant statement at this year’s IFA trade fair, occupying an expansive 2,600-square-meter exhibition space in Hall 5.1. The showcase will feature a diverse portfolio of home appliance and air conditioning solutions, with first-time participation from Küppersbusch Hausgeräte GmbH and its premium brands Küppersbusch and Teka, alongside U.S.-based vacuum cleaner specialist Eureka.

A Unified Platform for Global Brand Visibility

Under the overarching theme “Humanizing Technology,” Midea Group aims to highlight product innovations designed around user experience, energy efficiency, and lifestyle integration. For Küppersbusch and Teka, the event marks a strategic entry onto the IFA stage, allowing these European brands to strengthen their market positioning through direct engagement with international distributors, retailers, and technology partners.

SHERIDAN, WYOMING – August 10, 2025 – The GSMA is preparing to host one of the most significant technology gatherings of the decade as MWC Barcelona returns March 2–5, 2026, celebrating 20 years of convening global connectivity leaders. The milestone event aims to blend two decades of innovation with a forward-looking agenda focused on AI, 5G, enterprise technology, and policy shaping for the next generation of connected solutions.

Two Decades of Industry Collaboration and Impact

Since its inception, MWC Barcelona has served as a strategic platform where network operators, device manufacturers, policymakers, and technology investors converge. The event’s legacy is rooted in driving advancements in global communications, from the earliest mobile broadband rollouts to the current surge in edge computing, private networks, and IoT integration.

Elevating the Global Stage in 2026

SHERIDAN, WYOMING – August 10, 2025 – Eli Lilly is navigating a three-pronged challenge on drug pricing, from regulatory proposals to competitive market dynamics, even as it advances its next-generation oral weight loss candidate, orforglipron. On its second quarter earnings call, the company’s leadership underscored that pricing strategy will remain central to sustaining market share and delivering shareholder value.

Balancing Innovation and Pricing in Obesity Therapeutics

Lilly’s much-anticipated oral GLP-1 receptor agonist, orforglipron, is positioned to compete directly with Novo Nordisk’s blockbuster obesity portfolio. With the oral format offering improved patient convenience over injectable therapies, analysts expect robust uptake potential. However, the commercial rollout will hinge on a price point that supports payer coverage while defending against Most Favored Nation (MFN) pricing pressures at the federal level.

SHERIDAN, WYOMING – August 10, 2025 – Globus Medical, Inc. (NYSE: GMED) reported strong second-quarter 2025 results, achieving record non-GAAP earnings per share and double-digit revenue growth, driven by its U.S. Spine business and strategic integration of Nevro. The performance underscores the company’s operational discipline and its continued push to expand robotic-assisted surgery adoption.

Double-Digit Revenue Growth Across Core Segments

Worldwide net sales reached $745.3 million, an 18.4% year-over-year increase, or 17.6% on a constant currency basis. U.S. net sales rose 20.3%, while international revenue grew 11% as reported. The company’s Musculoskeletal Solutions segment generated $710.2 million, with Enabling Technologies contributing $35.2 million after a modest rebound in demand.

Operational Leverage and Profitability Milestones